Government Offers Ovarian Cancer Cell Line for License
Published Date: 6/16/2026
Notice
Summary
The National Cancer Institute is offering a special ovarian cancer cell line called A1847 for researchers to license and use. This cell line helps scientists study how ovarian cancer grows and find better treatments, especially for tough cases linked to BRCA1 gene problems. If you’re into cancer research, this is your chance to get a powerful tool starting now, with no big costs for licensing.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
A1847 Ovarian Cancer Cell Line Offered
The National Cancer Institute is offering the A1847 human ovarian carcinoma cell line for nonexclusive license (NIH Reference E-137-2023-0). The line is BRCA1-deficient, was derived from a 50-year-old female, and is karyotypically characterized with modal number 68 and 3 marker chromosomes; it is offered as a research material/tool for screening drug candidates, identifying therapeutic targets, and generating animal models for metastatic ovarian cancer.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-19706, Draft NIH Policy on Sharing Summary Level Study Results With Clinical Research Participants
The NIH wants to make it easier for people who join clinical studies to get simple summaries of the study results. This new policy aims to boost trust and teamwork between researchers and participants, helping science move faster and better. They’re asking for your thoughts by October 26, 2026, so get ready to share your ideas!
2026-19431, Government-Owned Inventions; Availability for Licensing
The government is offering a new invention for licensing that makes stem cell transplants safer and less harsh, especially for leukemia patients and older folks. This tech uses a special protein to prepare patients for transplants without the tough side effects of chemo and radiation. Companies can start licensing this preclinical innovation now to help bring better treatments to market faster.
2026-19303, Submission for OMB review; 30-Day Comment Request; the Impact and Costs of Promoting Objectivity in Research 42 CFR Part 50 Subpart F and Responsible Prospective Contractors 45 CFR Part 94 (Office of the Director)
The National Institutes of Health (NIH) is asking for your thoughts on how they collect info to keep research honest and fair. This affects researchers and contractors who work with NIH, aiming to make sure everything stays clear and trustworthy. You’ve got until October 22, 2026, to share your comments—no cost changes, just a check-in to keep things running smoothly!
2026-19155, Proposed Collection; 60-Day Comment Request; PHS Applications and Pre-Award Reporting Requirements (OD)
The NIH is updating how researchers submit their Public Health Service applications and reports before awards, starting May 25, 2026. This change aims to make data management clearer and easier, affecting anyone applying for NIH funding. They want your feedback by November 17, 2026, to help improve the process without adding extra hassle or costs.
2026-19156, Proposed Collection; 60-Day Comment Request; Post-Award Reporting Requirements Including Research Performance Progress Report (OD)
The National Institutes of Health (NIH) wants your thoughts on updating how researchers report their progress after getting awards. This affects anyone who receives NIH funding and aims to make reporting clearer and less of a hassle. Comments are due by November 17, 2026, so don’t miss your chance to weigh in!
2026-18937, Proposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form (Office of the Director/Office of Intramural Research)
The NIH is rolling out a new online form to make reporting research cheating easier and fairer. Anyone involved with NIH research can use this form to report problems like lying or copying, even anonymously. They want your feedback by November 16, 2026, to make sure the form works well without causing extra hassle.
Previous / Next Documents
Previous: 2026-12068, Boulder Canyon Project
The Western Area Power Administration is keeping the Boulder Canyon Project electric rates steady at $76.2 million for fiscal year 2027, starting October 1, 2026. This means no price hikes for customers in the Desert Southwest region. Public meetings and a comment period from June 16 to September 14, 2026, invite everyone to learn more and share their thoughts.
Next: 2026-12072, Foreign-Trade Zone 44; Application for Subzone; Perlen Packaging LLC; Whippany, New Jersey
Perlen Packaging LLC in Whippany, New Jersey, wants to join Foreign-Trade Zone 44 as a special subzone. This means they can enjoy some trade benefits, but no production changes are planned yet. The public can share their thoughts by July 27, 2026, so don’t miss your chance to weigh in!